Loading
A phase 1/2 trial of Pembrolizumab in salivary gland cancers and non-small-cell lung cancer, run by VM Oncology, LLC, now recruiting.
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma is a phase 1/2 interventional study registered as NCT03556228 by VM Oncology, LLC, with 242 participants planned, started 2018-06-08 and due to reach its primary completion in 2027-12. Interventions recorded: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg). Conditions listed: Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mesothelioma, Head and neck squamous cell carcinoma, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Mesothelioma, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Salivary gland cancers, Head and neck squamous cell carcinoma.
Shares Mesothelioma, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Salivary gland cancers, Head and neck squamous cell carcinoma.
Shares Mesothelioma, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Mesothelioma, Immune checkpoint inhibitors.
Shares Mesothelioma, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/